Jordan Zwick

Mr. Zwick is the Co-Founder and Chief Business Officer of Mirador Therapeutics and an experienced biopharmaceutical executive with expertise in corporate strategy, business development, capital markets and value creation across public and private life sciences companies. He has advised and led numerous strategic transactions throughout his career, including serving as a strategic advisor to Prometheus Biosciences prior to its acquisition by Merck in 2023 and to CrossBridge Bio through its acquisition by Eli Lilly in 2026. He was also a member of the Board of Directors and Audit Committee of Theratechnologies, Inc. prior to the company’s sale to Future Pak in 2025. Mr. Zwick served as Senior Vice President, Corporate Business Development and Investor Relations at Amarin Corporation and, previously, as Senior Vice President and Chief Strategy Officer at InflaRx N.V. Earlier in his career, he held positions at Medtronic, Salix Pharmaceuticals and Bausch Health. He currently serves on the Board of Directors of TruTechnologies, a portfolio company of LLR Partners, and on the Advisory Board of the McKenna Life Sciences, Business and Entrepreneurship Program at Arizona State University.